article Open AccessTop 1% cited
The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
Bioorganic & Medicinal Chemistry Letters · 1999 · Vol. 9(13) · pp. 1773–1778
Petpiboon Prasit✉(Merck Canada Inc. (Canada))Z Wang(Merck Canada Inc. (Canada))Christine Brideau(Merck Canada Inc. (Canada))Chi‐Chung Chan(Merck Canada Inc. (Canada))S. Charleson(Merck Canada Inc. (Canada))Wanda Cromlish(Merck Canada Inc. (Canada))Diane Ethier(Merck Canada Inc. (Canada))Jilly F. Evans(Merck Canada Inc. (Canada))A W Ford‐Hutchinson(Merck Canada Inc. (Canada))J. Y. GAUTHIER(Merck Canada Inc. (Canada))Robert J. Gordon(Merck Canada Inc. (Canada))Jocelyne Guay(Merck Canada Inc. (Canada))Michael J. Gresser(Merck Canada Inc. (Canada))Stacia Kargman(Merck Canada Inc. (Canada))Brian P. Kennedy(Merck Canada Inc. (Canada))Y. LEBLANC(Merck Canada Inc. (Canada))Serge Léger(Merck Canada Inc. (Canada))Joseph A. Mancini(Merck Canada Inc. (Canada))Gary P. O’Neill(Merck Canada Inc. (Canada))Marc Ouellet(Merck Canada Inc. (Canada))M. David Percival(Merck Canada Inc. (Canada))H. Perrier(Merck Canada Inc. (Canada))Denis Riendeau(Merck Canada Inc. (Canada))Ian W. Rodger(Merck Canada Inc. (Canada))Philip Tagari(Merck Canada Inc. (Canada))Michel Thérien(Merck Canada Inc. (Canada))Philip J. Vickers(Merck Canada Inc. (Canada))Elizabeth Wong(Merck Canada Inc. (Canada))Li-Jing Xu(Merck Canada Inc. (Canada))Robert N. Young(Merck Canada Inc. (Canada))Robert Zamboni(Merck Canada Inc. (Canada))S. Boyce(Merck (United Kingdom))N.M.J. Rupniak(Merck (United Kingdom))M J ForrestDenise M. ViscoD Patrick
Inflammatory mediators and NSAID effectsEstrogen and related hormone effectsSynthesis of β-Lactam CompoundsRofecoxibChemistryCyclooxygenaseIn vivoPharmacologyOrally activeEnzyme inhibitorCOX-2 inhibitorProstaglandin-Endoperoxide SynthaseOral administration
MeSH terms
Administration, OralAnimalsBiological AvailabilityEnzyme InhibitorsCricetinaeHumansIndomethacinIsoenzymesLactonesMembrane ProteinsProstaglandin-Endoperoxide SynthasesSulfonesCHO CellsCyclooxygenase InhibitorsInhibitory Concentration 50
Citations
427
FWCI
12.62
field-weighted impact
References
20
Percentile
99%
vs. same field & year
Citations per year
References
Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1<i>H</i>-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)
Journal of Medicinal Chemistry · 1997 · 1,949 citations
Risk of Alzheimer's disease and duration of NSAID use
Neurology · 1997 · 1,122 citations
Related articles
The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
Bioorganic & Medicinal Chemistry Letters · 1999 · 427 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.